Cargando…
Correlation between initial tumour volume and treatment duration on Dabrafenib: observation study of subjects with BRAF mutant melanoma on the BRF112680 trial
BACKGROUND: Planar-based measurements of lesions in metastatic melanoma have limitations in estimating tumor burden of a patient and in predicting response to treatment. Volumetric imaging might add predictive value to Response criteria in Solid Tumor (RECIST)-measurement. Based on clinical observat...
Autores principales: | Ali, Arwa, Dumbrava, Monica, Riddell, Kylie, Stewart, Nina, Ward, Robyn, Ibrahim, Ahmed K., Chin, Melvin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7179008/ https://www.ncbi.nlm.nih.gov/pubmed/32321474 http://dx.doi.org/10.1186/s12885-020-06848-8 |
Ejemplares similares
-
Dabrafenib for treatment of BRAF-mutant melanoma
por: Kainthla, Radhika, et al.
Publicado: (2013) -
Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2019) -
Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive BRAF Mutant Advanced Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2023) -
Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma
por: Homet Moreno, Blanca, et al.
Publicado: (2015) -
Dabrafenib: A New Therapy for Use in BRAF-Mutated Metastatic Melanoma
por: McGettigan, Suzanne
Publicado: (2014)